Protagonist Therapeutics Inc PTGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
-
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
-
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
-
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
-
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
-
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda
Trading Information
- Previous Close Price
- $44.93
- Day Range
- $44.30–45.27
- 52-Week Range
- $13.72–48.00
- Bid/Ask
- $44.54 / $44.55
- Market Cap
- $2.62 Bil
- Volume/Avg
- 661,880 / 960,188
Key Statistics
- Price/Earnings (Normalized)
- 16.63
- Price/Sales
- 8.64
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- < 0.01%
Company Profile
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 125
- Website
- https://www.protagonist-inc.com
Comparables
Valuation
|
Metric
|
PTGX
|
ACLX
|
LYEL
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.63 | — | — |
Price/Book Value | 4.84 | 9.11 | 0.68 |
Price/Sales | 8.64 | 29.11 | 7,089.20 |
Price/Cash Flow | 13.83 | 536.38 | — |
Price/Earnings
PTGX
ACLX
LYEL
Financial Strength
|
Metric
|
PTGX
|
ACLX
|
LYEL
|
|---|---|---|---|
Quick Ratio | 13.60 | 5.85 | 15.90 |
Current Ratio | 13.73 | 6.01 | 16.19 |
Interest Coverage | — | −28.35 | — |
Quick Ratio
PTGX
ACLX
LYEL
Profitability
|
Metric
|
PTGX
|
ACLX
|
LYEL
|
|---|---|---|---|
Return on Assets (Normalized) | 44.65% | −1.88% | −21.42% |
Return on Equity (Normalized) | 49.43% | −3.31% | −24.51% |
Return on Invested Capital (Normalized) | 44.16% | −7.10% | −26.29% |
Return on Assets
PTGX
ACLX
LYEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fkknxtkdr | Rdw | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xmtsdrs | Mhfrtqb | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bjsjmpwdp | Tvphgm | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wghpjjqj | Sdgwlty | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Wsfpcxft | Phxwh | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xzvyvlbvj | Dnsj | $28.1 Bil | |||
| Moderna Inc
MRNA
| Hzxyncz | Gbb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Gvpwzhmjj | Nwjky | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nvygqgtv | Tjyvmxx | $13.4 Bil | |||
| Incyte Corp
INCY
| Hgymylnsg | Ffpxbq | $12.7 Bil |
United States